Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) released its earnings results on Thursday. The company reported ($1.56) EPS for the quarter, topping analysts’ consensus estimates of ($11.12) by $9.56, Zacks reports.
Sonnet BioTherapeutics Stock Performance
NASDAQ SONN opened at $1.54 on Friday. Sonnet BioTherapeutics has a 12 month low of $1.41 and a 12 month high of $18.72. The company’s 50 day moving average is $1.65 and its two-hundred day moving average is $2.24.
Wall Street Analyst Weigh In
Separately, Chardan Capital decreased their target price on shares of Sonnet BioTherapeutics from $30.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, December 20th.
About Sonnet BioTherapeutics
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Featured Articles
- Five stocks we like better than Sonnet BioTherapeutics
- The Most Important Warren Buffett Stock for Investors: His Own
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Cisco Roars Back: Is the Tech Giant Reborn?
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Albemarle’s Earnings Are In—Is the Stock a Buy Now?
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
